These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12039426)

  • 1. The mitochondrial common deletion in Parkinson's disease and related movement disorders.
    Zhang J; Montine TJ; Smith MA; Siedlak SL; Gu G; Robertson D; Perry G
    Parkinsonism Relat Disord; 2002 Jan; 8(3):165-70. PubMed ID: 12039426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders.
    Gu G; Reyes PE; Golden GT; Woltjer RL; Hulette C; Montine TJ; Zhang J
    J Neuropathol Exp Neurol; 2002 Jul; 61(7):634-9. PubMed ID: 12125742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons.
    Zhang J; Perry G; Smith MA; Robertson D; Olson SJ; Graham DG; Montine TJ
    Am J Pathol; 1999 May; 154(5):1423-9. PubMed ID: 10329595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Bukhatwa S; Zeng BY; Rose S; Jenner P
    Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
    Taniguchi D; Hatano T; Kamagata K; Okuzumi A; Oji Y; Mori A; Hori M; Aoki S; Hattori N
    Mov Disord; 2018 Sep; 33(9):1488-1492. PubMed ID: 29756366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease.
    Sanders LH; McCoy J; Hu X; Mastroberardino PG; Dickinson BC; Chang CJ; Chu CT; Van Houten B; Greenamyre JT
    Neurobiol Dis; 2014 Oct; 70():214-23. PubMed ID: 24981012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
    Hattori N
    Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lewy body pathology is associated with mitochondrial DNA damage in Parkinson's disease.
    Müller SK; Bender A; Laub C; Högen T; Schlaudraff F; Liss B; Klopstock T; Elstner M
    Neurobiol Aging; 2013 Sep; 34(9):2231-3. PubMed ID: 23566333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aging on magnetic resonance measures differentiating progressive supranuclear palsy from Parkinson's disease.
    Morelli M; Arabia G; Messina D; Vescio B; Salsone M; Chiriaco C; Perrotta P; Rocca F; Cascini GL; Barbagallo G; Nigro S; Quattrone A
    Mov Disord; 2014 Apr; 29(4):488-95. PubMed ID: 24573655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detrimental deletions: mitochondria, aging and Parkinson's disease.
    Biskup S; Moore DJ
    Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lewy body-related alpha-synucleinopathy in the aged human brain.
    Jellinger KA
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1219-35. PubMed ID: 15480835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans.
    Mawrin C; Kirches E; Krause G; Schneider-Stock R; Bogerts B; Vorwerk CK; Dietzmann K
    Neurosci Lett; 2004 Mar; 357(2):111-4. PubMed ID: 15036587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New and reliable MRI diagnosis for progressive supranuclear palsy.
    Oba H; Yagishita A; Terada H; Barkovich AJ; Kutomi K; Yamauchi T; Furui S; Shimizu T; Uchigata M; Matsumura K; Sonoo M; Sakai M; Takada K; Harasawa A; Takeshita K; Kohtake H; Tanaka H; Suzuki S
    Neurology; 2005 Jun; 64(12):2050-5. PubMed ID: 15985570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell death mechanisms in Parkinson's disease.
    Jellinger KA
    J Neural Transm (Vienna); 2000; 107(1):1-29. PubMed ID: 10809400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?
    Mouatt-Prigent A; Karlsson JO; Agid Y; Hirsch EC
    Neuroscience; 1996 Aug; 73(4):979-87. PubMed ID: 8809817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy.
    Eraslan C; Acarer A; Guneyli S; Akyuz E; Aydin E; Colakoglu Z; Kitis O; Calli MC
    Neurol Res; 2019 Feb; 41(2):110-117. PubMed ID: 30373485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Eye Movement Impairment Correlate with Regional Brain Atrophy in Neurodegenerative Parkinsonism.
    Vintonyak O; Gorges M; Müller HP; Pinkhardt EH; Ludolph AC; Huppertz HJ; Kassubek J
    Neurodegener Dis; 2017; 17(4-5):117-126. PubMed ID: 28268209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
    Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
    Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
    Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.